Description
Heart Tumor Market Research Report – Forecast till 2030
Market Overview
The Heart Tumor Market is anticipated to register a significant CAGR of 6.31% during the forecast period owing to the market value of USD 783.34 million in 2021. A cardiac tumor is an abnormal development of the heart that can be either cancerous (malignant) or non-cancerous. Primary (arising from the heart itself) and secondary cardiac tumors are further classifications for the disease.
A primary heart tumor only affects about 1 in 3000 persons, making it incredibly rare. 20–30 times more often than the main cardiac tumor, the secondary cardiac tumor typically arises in patients with lung cancer, breast cancer, melanoma, renal cell carcinoma, or lymphoma.
The market is fueled by variables such as the rising incidence of cardiac tumors, the rising financing and quantity of cancer research projects, and the rising number of strategic initiatives. However, it is projected that expanding efforts by public and private organizations to raise awareness about heart tumors would present profitable prospects for market participants.
The development of the heart tumor market, however, may be constrained by a lack of public knowledge and a shortage of radiologists with the necessary skills. One of the key drivers propelling the heart tumor market is the rising prevalence of heart tumors, including cardiac sarcoma, arrhythmia, chest discomfort, stroke, and pericardial effusion. Additionally, rising asymptomatic carriers and rising cardiac sarcoma rates, particularly during the COVID-19 pandemic, have further fueled the market expansion.
Segment Overview
Global Heart Tumor Market is divided based on Tumor Type and Diagnosis & Treatment. Based on the tumor type the market is bifurcated into Primary Tumor and Secondary Tumor. By Diagnosis & Treatment, the market is divided into Diagnosis and Treatment. The diagnosis segment is further categorized into CT scan, MRI Scan, Nuclear Imaging, Echocardiography, and Others. Whereas the treatment type is further classified into Surgery, Chemotherapy, Radiotherapy, and Others.
Regional Analysis
Based on region, North America had the greatest market share, or 40.72%, and is expected to rule the global market for heart tumors over the projection period. North America includes the United States and Canada. In 2021, North America accounted for the greatest market share. This is because of things like the widespread usage of cardiac biopsies and the high incidence of PCTs. Primary Malignant Cardiac Tumors (PMCTs), a subset of Primary Cardiac Tumors (PCTs), are more common in North America and Europe than in other countries, which is supporting the market for heart tumors. Over the projected period, Asia-Pacific is expected to have the greatest CAGR, at 8.06%. This is because of elements like the presence off a few critical organizations and they are effectively money management and extending through acquisitions, consolidations, development, and item dispatches in the locale.
Major Players
The prominent players in the heart Tumor market include Boston Scientific Corporation (US), FUJIFILM Corporation (Japan), GE Healthcare (US), Siemens (Germany), Amneal Pharmaceuticals llc (US), Shimadzu Corporation (Japan), TomTec Imaging Systems GmbH (Germany), Koninklijke Philips N.V (The Netherlands), Toshiba Corporation (Japan), and Terumo cardiovascular systems corporation (US).
COVID 19 Impacts
We are continuously tracking the impact of the COVID-19 pandemic on various industries and verticals within all domains. Our research reports include the same and help you understand the drop and rise, owing to the impact of COVID-19 on industries. Also, we help you to identify the gap between the demand and supply of your interested market. Moreover, the report helps you with the analysis, amended government regulations, and many other useful insights.
TABLE OF CONTENTS
1 EXECUTIVE SUMMARY
1.1 OVERVIEW
2 MARKET INTRODUCTION
2.1 DEFINITION
2.2 SCOPE OF THE STUDY
2.3 RESEARCH OBJECTIVE
2.4 LIST OF ASSUMPTIONS
3 RESEARCH METHODOLOGY
3.1 OVERVIEW
3.2 DATA MINING
3.3 SECONDARY RESEARCH
3.4 PRIMARY RESEARCH
3.4.1 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS
3.4.2 BREAKDOWN OF PRIMARY RESPONDENTS
3.5 FORECASTING TECHNIQUES
3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION
3.6.1 BOTTOM-UP APPROACH
3.6.2 TOP-DOWN APPROACH
3.7 DATA TRIANGULATION
3.8 VALIDATION
4 MARKET DYNAMICS
4.1 OVERVIEW
4.2 DRIVERS
4.2.1 GROWING PREVALENCE OF CARDIAC TUMORS
4.2.2 INCREASING NUMBER OF CANCER RESEARCH AND FUNDING
4.2.3 RISING NUMBER OF STRATEGIC INITIATIVES
4.3 RESTRAINTS
4.3.1 LACK OF AWARENESS AMONG PEOPLE
4.3.2 LACK OF SKILLED RADIOLOGISTS
4.4 OPPORTUNITIES
4.4.1 INCREASING INITIATIVES BY PUBLIC AND PRIVATE ORGANIZATIONS TO DRIVE AWARENESS REGARDING HEART TUMOR
5 MARKET FACTOR ANALYSIS
5.1 VALUE CHAIN ANALYSIS
5.1.1 R&D
5.1.2 MANUFACTURING
5.1.3 DISTRIBUTION & SALES
5.1.4 POST-SALES MONITORING
5.2 PORTER’S FIVE FORCES MODEL
5.2.1 THREAT OF NEW ENTRANTS
5.2.2 BARGAINING POWER OF SUPPLIERS
5.2.3 THREAT OF SUBSTITUTES
5.2.4 BARGAINING POWER OF BUYERS
5.2.5 INTENSITY OF RIVALRY
5.3 IMPACT OF COVID-19 ON THE HEART TUMOR MARKET
5.3.1 IMPACT ON SUPPLY CHAIN
5.3.2 IMPACT ON PRODUCTION
5.3.3 IMPACT ON KEY PLAYERS
5.3.4 IMPACT ON REGION
6 GLOBAL HEART TUMOR MARKET, TUMOR TYPE
6.1 OVERVIEW
6.2 PRIMARY TUMOR
6.3 SECONDARY TUMOR
7 GLOBAL HEART TUMOR MARKET, BY DIAGNOSIS & TREATMENT
7.1 OVERVIEW
7.2 DIAGNOSIS
7.2.1 CT SCAN
7.2.2 MRI SCAN
7.2.3 NUCLEAR IMAGING
7.2.4 ECHOCARDIOGRAPHY
7.2.5 OTHERS
7.3 TREATMENT
7.3.1 COST PER PROCEDURE
7.3.2 SURGERY
7.3.3 CHEMOTHERAPY
7.3.4 RADIOTHERAPY
7.3.5 OTHERS
8 GLOBAL HEART TUMOR MARKET, BY REGION
8.1 OVERVIEW
8.2 NORTH AMERICA
8.2.1 US
8.2.2 CANADA
8.3 EUROPE
8.3.1 GERMANY
8.3.2 UK
8.3.3 FRANCE
8.3.4 ITALY
8.3.5 SPAIN
8.3.6 REST OF EUROPE
8.4 ASIA-PACIFIC
8.4.1 JAPAN
8.4.2 CHINA
8.4.3 INDIA
8.4.4 AUSTRALIA
8.4.5 SOUTH KOREA
8.4.6 REST OF ASIA-PACIFIC
8.5 REST OF THE WORLD
8.5.1 MIDDLE EAST
8.5.2 AFRICA
8.5.3 LATIN AMERICA
9 COMPETITIVE LANDSCAPE
9.1 OVERVIEW
9.2 COMPETITIVE BENCHMARKING
9.3 MAJOR GROWTH STRATEGY IN THE GLOBAL HEART TUMOR MARKET
9.4 THE LEADING PLAYER IN TERMS OF THE NUMBER OF DEVELOPMENTS IN THE GLOBAL HEART TUMOR MARKET
9.5 KEY DEVELOPMENT ANALYSIS
9.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
9.6.1 PRODUCT LAUNCH/ PRODUCT APPROVAL
9.6.2 PARTERSHIP/AGREEMENT
9.6.3 MERGER /ACQUISTION
9.6.4 EXPANSION /INVESTMENT
9.7 FINANCIAL MATRIX
9.7.1 SALES (USD MILLION), 2021
9.7.2 R&D EXPENDITURE (USD MILLION), 2021
10 COMPANY PROFILE
10.1 KONINKLIJKE PHILIPS N.V.
10.1.1 COMPANY OVERVIEW
10.1.2 FINANCIAL OVERVIEW
10.1.3 PRODUCTS/SERVICES OFFERED
10.1.4 KEY DEVELOPMENTS
10.1.5 SWOT ANALYSIS
10.1.6 KEY STRATEGIES
10.2 FUJIFILM CORPORATION
10.2.1 COMPANY OVERVIEW
10.2.2 FINANCIAL OVERVIEW
10.2.3 PRODUCTS OFFERED
10.2.4 KEY DEVELOPMENTS
10.2.5 SWOT ANALYSIS
10.2.6 KEY STRATEGIES
10.3 GE HEALTHCARE
10.3.1 COMPANY OVERVIEW
10.3.2 FINANCIAL OVERVIEW
10.3.3 PRODUCTS OFFERED
10.3.4 KEY DEVELOPMENTS
10.3.5 SWOT ANALYSIS
10.3.6 KEY STRATEGIES
10.4 SIEMENS
10.4.1 COMPANY OVERVIEW
10.4.2 FINANCIAL OVERVIEW
10.4.3 PRODUCTS OFFERED
10.4.4 KEY DEVELOPMENTS
10.4.5 KEY STRATEGIES
10.5 AMNEAL PHARMACEUTICALS LLC
10.5.1 COMPANY OVERVIEW
10.5.2 FINANCIAL OVERVIEW
10.5.3 PRODUCTS OFFERED
10.5.4 KEY DEVELOPMENTS
10.5.5 KEY STRATEGIES
10.6 SHIMADZU CORPORATION
10.6.1 COMPANY OVERVIEW
10.6.2 FINANCIAL OVERVIEW
10.6.3 PRODUCTS OFFERED
10.6.4 KEY DEVELOPMENTS
10.6.5 SWOT ANALYSIS
10.6.6 KEY STRATEGIES
10.7 TOMTEC IMAGING SYSTEMS GMBH
10.7.1 COMPANY OVERVIEW
10.7.2 FINANCIAL OVERVIEW
10.7.3 PRODUCTS OFFERED
10.7.4 KEY DEVELOPMENTS
10.7.5 KEY STRATEGIES
10.8 TOSHIBA CORPORATION
10.8.1 COMPANY OVERVIEWS
10.8.2 FINANCIAL OVERVIEW
10.8.3 PRODUCTS TOSHIBA CORPORATION OFFERED
10.8.4 KEY DEVELOPMENTS
10.8.5 SWOT ANALYSIS
10.8.6 KEY STRATEGIES
10.9 BOSTON SCIENTIFIC CORPORATION
10.9.1 COMPANY OVERVIEW
10.9.2 FINANCIAL OVERVIEW
10.9.3 PRODUCTS OFFERED
10.9.4 KEY DEVELOPMENTS
10.9.5 KEY STRATEGIES
10.10 TERUMO CARDIOVASCULAR SYSTEMS CORPORATION
10.10.1 COMPANY OVERVIEW
10.10.2 FINANCIAL OVERVIEW
10.10.3 PRODUCTS OFFERED
10.10.4 KEY DEVELOPMENTS
10.10.5 KEY STRATEGIES
11 APPENDIX
11.1 REFERENCES
11.2 RELATED REPORTS
Reviews
There are no reviews yet.